Results 231 to 240 of about 14,337,199 (401)

High Troponin I in Patients Following Off-pump Coronary Artery Bypass Grafting. [PDF]

open access: yesCard Fail Rev
Cui H   +8 more
europepmc   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai   +4 more
wiley   +1 more source

Clinical Significance of Cardiac Troponin I Elevation in Detecting Immune Checkpoint Inhibitor-Induced Myocarditis. [PDF]

open access: yesCirc Rep
Oikawa M   +9 more
europepmc   +1 more source

Evaluation of High-Sensitivity Cardiac Troponin I Levels in Patients With Suspected Acute Coronary Syndrome.

open access: yesJAMA cardiology, 2016
E. Carlton   +13 more
semanticscholar   +1 more source

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

open access: yesESC Heart Failure, EarlyView.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori   +9 more
wiley   +1 more source

Cardiac-specific troponin-I (cTnI) in a post-mortem setting. [PDF]

open access: yesInt J Legal Med
Sutton ED   +3 more
europepmc   +1 more source

Functional recovery of troponin I in a Drosophila heldup mutant after a second site mutation. [PDF]

open access: green, 1995
Antonio Prado   +4 more
openalex   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

open access: yesESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra   +25 more
wiley   +1 more source

Home - About - Disclaimer - Privacy